Skip to main content

Table 2 Susceptibility of serial passaged HSV-1 SC16 isolates to PCV as measured by the PRA.

From: Absence of rapid selection for acyclovir or penciclovir resistance following suboptimal oral prodrug therapy of HSV-infected mice

Parental SC16a

Passage No.

PCV IC50 (μg/ml)

  

Placebo

FCV

VCV

0.39

1

0.36 ± 0.04b

0.42 ± 0.07

0.42 ± 0.05

0.57

2

0.48 ± 0.16

0.76 ± 0.23

0.74 ± 0.35

0.90

3

0.33 ± 0.08

0.50 ± 0.24

0.49 ± 0.36

0.73

4

1.13+0.46

1.31 ± 0.42

2.73 ± 3.11c

0.77

5

1.15 ± 0.24

0.68 ± 0.15

0.68 ± 0.07

0.70

6

0.79 ± 0.13

0.74 ± 0.09

0.80+0.12

0.70

7

0.81 ± 0.38

0.57 ± 0.27

0.66 ± 0.24

  1. aIC50 against PCV for the original parental control virus preparation (not passaged in mice). bIC50 against PCV ± standard deviation for test isolates for n = 5 samples. cIC50 (μgml) PCV for samples 26–30 ranged from 1.09–8.3.
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us